C M Bidwell & Associates Ltd. Buys 337 Shares of Cencora, Inc. (NYSE:COR)

C M Bidwell & Associates Ltd. grew its stake in Cencora, Inc. (NYSE:COR) by 28.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,509 shares of the company’s stock after purchasing an additional 337 shares during the quarter. C M Bidwell & Associates Ltd.’s holdings in Cencora were worth $339,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of COR. FSB Premier Wealth Management Inc. raised its stake in Cencora by 8.6% in the fourth quarter. FSB Premier Wealth Management Inc. now owns 2,281 shares of the company’s stock worth $512,000 after buying an additional 180 shares in the last quarter. O Shaughnessy Asset Management LLC grew its holdings in shares of Cencora by 16.7% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 52,965 shares of the company’s stock worth $11,900,000 after acquiring an additional 7,597 shares during the period. United Bank raised its position in shares of Cencora by 15.8% in the 4th quarter. United Bank now owns 6,487 shares of the company’s stock worth $1,457,000 after acquiring an additional 886 shares in the last quarter. RWA Wealth Partners LLC raised its position in shares of Cencora by 1.8% in the 4th quarter. RWA Wealth Partners LLC now owns 33,983 shares of the company’s stock worth $7,635,000 after acquiring an additional 586 shares in the last quarter. Finally, Schroder Investment Management Group purchased a new position in shares of Cencora in the 4th quarter valued at approximately $41,378,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Performance

COR stock opened at $275.16 on Monday. The stock’s 50 day simple moving average is $253.81 and its 200 day simple moving average is $241.24. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $275.57. The stock has a market capitalization of $53.36 billion, a PE ratio of 39.14, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s payout ratio is presently 31.29%.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of research reports. Wells Fargo & Company increased their price objective on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday, March 14th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Mizuho started coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective on the stock. Finally, StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $280.20.

Insider Transactions at Cencora

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the company’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. This represents a 21.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 14,578 shares of the company’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares of the company’s stock, valued at approximately $85,680,732.63. The trade was a 4.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock worth $8,034,778 over the last three months. 10.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.